Single User License
INR 236215
Site License
INR 472430
Corporate User License
INR 708645

Service Tax Additional

select a format
Price

Single User License
USD 3500
Site License
USD 7000
Corporate User License
USD 10500

Alternatively

Request a quote
Request a Customized research
Request for Sample Report





Recent Viewed Reports


Why Ken Reasearch?


Testimonials

While we still are studying and analysing your reports about Vietnam & Thailand, we would like to convey to your research team that they have done a very good job in compiling so much of information together. We hope to see more of such well researched reports. All the best & keep it up. ... "Prashant Bhagwat,General Manager, Mahindra"

We would like to appreciate Ken Research for their great efforts and wonderful support in providing the Market Intelligence Report for ITPC. The information, statistics and research are well understandable and very clear to the point. We are happy with Ken research for their good client service, on-time delivery of the report and as said the report itself. Thank you Ken research for bringing the valuable output for us. We would be looking forward to have more research with you in the near future. Wish you a success in your business!... "Jestin Mathew, Indonesian Trade Promotion Center"

The Report was very interesting and useful for me... "Marketing Manager, Western Union Business Solutions"

Ken Research completed the report successfully with tough deadline and large requirement. Really appreciate it... "Sales Manager, Largest India Aesthetic Laser Manufacturer"

We found the report really useful in understanding the complex Indian market and it provided lots of high quality insights. On the basis of this we commissioned Ken to produce a bespoke follow up to answer some specific questions about our market. This is now being used to help develop our marketing and sales strategy. We were very pleased with the comprehensive coverage, detail provided and actionable insights.... "Owner, Therefore Consulting UK"


Human Cytomegalovirus Envelope Glycoprotein B (gB)-Pipeline Review, H2 2016

Human Cytomegalovirus Envelope Glycoprotein B (gB)-Pipeline Review, H2 2016


  Request for Sample Report

Executive Summary

Human Cytomegalovirus Envelope Glycoprotein B (gB)-Pipeline Review, H2 2016

Summary

Global Markets Direct's, 'Human Cytomegalovirus Envelope Glycoprotein B (gB)-Pipeline Review, H2 2016', provides in depth analysis on Human Cytomegalovirus Envelope Glycoprotein B (gB) targeted pipeline therapeutics.

The report provides comprehensive information on the Human Cytomegalovirus Envelope Glycoprotein B (gB), targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Human Cytomegalovirus Envelope Glycoprotein B (gB) targeted therapeutics development and features dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note:

*Certain sections in the report may be removed or altered based on the availability and relevance of data.

*Updated report will be delivered in 48 hours of order confirmation.

Scope

The report provides a snapshot of the global therapeutic landscape for Human Cytomegalovirus Envelope Glycoprotein B (gB)

The report reviews Human Cytomegalovirus Envelope Glycoprotein B (gB) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved in Human Cytomegalovirus Envelope Glycoprotein B (gB) targeted therapeutics and enlists all their major and minor projects

The report assesses Human Cytomegalovirus Envelope Glycoprotein B (gB) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news and deals related to Human Cytomegalovirus Envelope Glycoprotein B (gB) targeted therapeutics

Reasons To Buy

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand the targeted therapy areas and indications for Human Cytomegalovirus Envelope Glycoprotein B (gB)

Identify the use of drugs for target identification and drug repurposing

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Human Cytomegalovirus Envelope Glycoprotein B (gB) development landscape

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Table of Contents

Table of Contents 2

List of Tables 4

List of Figures 4

Introduction 5

Global Markets Direct Report Coverage 5

Human Cytomegalovirus Envelope Glycoprotein B (gB) Overview 6

Therapeutics Development 7

Human Cytomegalovirus Envelope Glycoprotein B (gB)-Products under Development by Stage of Development 7

Human Cytomegalovirus Envelope Glycoprotein B (gB)-Products under Development by Therapy Area 8

Human Cytomegalovirus Envelope Glycoprotein B (gB)-Products under Development by Indication 9

Human Cytomegalovirus Envelope Glycoprotein B (gB)-Pipeline Products Glance 10

Late Stage Products 10

Early Stage Products 11

Human Cytomegalovirus Envelope Glycoprotein B (gB)-Products under Development by Companies 12

Human Cytomegalovirus Envelope Glycoprotein B (gB)-Therapeutics Assessment 14

Assessment by Monotherapy/Combination Products 14

Assessment by Mechanism of Action 15

Assessment by Route of Administration 16

Assessment by Molecule Type 17

Human Cytomegalovirus Envelope Glycoprotein B (gB)-Companies Involved in Therapeutics Development 19

Astellas Pharma Inc. 19

Trellis Bioscience, Inc. 20

Vakzine Projekt Management GmbH 21

VBI Vaccines Inc 22

Vical Incorporated 23

Human Cytomegalovirus Envelope Glycoprotein B (gB)-Drug Profiles 24

ASP-0113-Drug Profile 24

Product Description 24

Mechanism Of Action 24

R&D Progress 24

CyMVectin-Drug Profile 27

Product Description 27

Mechanism Of Action 27

R&D Progress 27

TRL-345-Drug Profile 29

Product Description 29

Mechanism Of Action 29

R&D Progress 29

VBI-1501A-Drug Profile 30

Product Description 30

Mechanism Of Action 30

R&D Progress 30

VBI-1901-Drug Profile 32

Product Description 32

Mechanism Of Action 32

R&D Progress 32

VPM-2001-Drug Profile 34

Product Description 34

Mechanism Of Action 34

R&D Progress 34

Human Cytomegalovirus Envelope Glycoprotein B (gB)-Dormant Projects 35

Human Cytomegalovirus Envelope Glycoprotein B (gB)-Featured News & Press Releases 36

Aug 22, 2016: VBI Vaccines to Continue Enrolling Participants in the Phase I Trial of its Preventative Cytomegalovirus Vaccine Candidate Following Successful Data Safety Monitoring Board Review 36

Jun 23, 2016: VBI Vaccines Begins Enrolling Patients in a Phase I Trial of its Preventative Cytomegalovirus Vaccine Candidate 36

Jun 16, 2016: VBI Vaccines Announces Medulloblastoma Immunotherapy Program 37

Mar 29, 2016: VBI To Present At The World Vaccine Congress Washington 38

Mar 07, 2016: VBI Vaccines Presents New Data Supporting its Glioblastoma Immunotherapy Program at the Keystone Symposia Cancer Vaccines Conference 38

Nov 20, 2015: VBI Vaccines Presents Update and New Data Supporting its Glioblastoma Immunotherapy Program at the ESMO Symposium on Immuno-Oncology 40

Nov 06, 2015: VBI Vaccines to Present Update and New Data Supporting its CMV Vaccine Program at the World Vaccine Congress Europe 41

Aug 26, 2015: VBI Vaccines to Provide an Update on its CMV Vaccine Program at the Tenth Annual IMVACS Summit 42

May 21, 2015: Vical Announces Completion of Enrollment in Phase 2 Clinical Trial of Investigational CMV Vaccine in Kidney Transplant Recipients 42

Apr 21, 2015: Vical Announces Presentation of Preclinical Data for Congenital CMV DNA Vaccine at International Conference 43

Apr 09, 2015: VBI Vaccines Announces New Data Supporting the Manufacture of Its Prophylactic CMV Vaccine Candidate 43

Nov 24, 2014: VBI To Present At The LD Micro Conference 44

Sep 15, 2014: New Data Supporting VBI's Prophylactic Cytomegalovirus (CMV) Vaccine Candidate (VBI-1501A) Presented at the 54th ICAAC Conference in Washington, D.C. 44

Mar 27, 2014: VBI Begins GMP Tech Transfer to Paragon Bioservices 45

Dec 10, 2013: Astellas and Vical Announce Initiation of Phase 2 Trial of ASP0113, a Cytomegalovirus Vaccine, in Solid Organ Transplant Recipients 45

Appendix 46

Methodology 46

Coverage 46

Secondary Research 46

Primary Research 46

Expert Panel Validation 46

Contact Us 46

Disclaimer 47

List of Figures

Number of Products under Development for, H2 2016 7

Number of Products under Development by Therapy Area, H2 2016 8

Number of Products under Development by Indication, H2 2016 9

Comparative Analysis by Early Stage Products, H2 2016 11

Assessment by Monotherapy/Combination Products, H2 2016 14

Number of Products by Stage and Routes of Administration, H2 2016 16

Number of Products by Molecule Types, H2 2016 17

Number of Products by Stage and Molecule Type, H2 2016 17

List of Tables

Number of Products under Development for, H2 2016 7

Number of Products under Development by Therapy Area, H2 2016 8

Number of Products under Development by Indication, H2 2016 9

Comparative Analysis by Late Stage Development, H2 2016 10

Comparative Analysis by Early Stage Products, H2 2016 11

Number of Products under Development by Companies, H2 2016 12

Products under Development by Companies, H2 2016 13

Assessment by Monotherapy/Combination Products, H2 2016 14

Number of Products by Stage and Mechanism of Action, H2 2016 15

Number of Products by Stage and Route of Administration, H2 2016 16

Number of Products by Stage and Molecule Type, H2 2016 18

Pipeline by Astellas Pharma Inc., H2 2016 19

Pipeline by Trellis Bioscience, Inc., H2 2016 20

Pipeline by Vakzine Projekt Management GmbH, H2 2016 21

Pipeline by VBI Vaccines Inc, H2 2016 22

Pipeline by Vical Incorporated, H2 2016 23

Dormant Projects, H2 2016 35

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to query [@] kenresearch.com
 

Astellas Pharma Inc.

Trellis Bioscience, Inc.

Vakzine Projekt Management GmbH

VBI Vaccines Inc

Vical Incorporated

Human Cytomegalovirus Envelope Glycoprotein B (gB) Therapeutic Products under Development, Key Players in Human Cytomegalovirus Envelope Glycoprotein B (gB) Therapeutics, Human Cytomegalovirus Envelope Glycoprotein B (gB) Pipeline Overview, Human Cytomegalovirus Envelope Glycoprotein B (gB) Pipeline, Human Cytomegalovirus Envelope Glycoprotein B (gB) Pipeline Assessment


Related Products in vertical
Other reports by publisher
Ken Research Pvt. Ltd. 27A, Tower B-2, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India
+91 1244230204

download

Company Brochure

Engage with Us

query [@] kenresearch.com